Certoparin in Renal Patients Undergoing Hemodialysis

A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis

This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.

Inclusion Criteria:

• Patients requiring hemodialysis
• Patients requiring anticoagulation therapy during hemodialysis
• Written informed consent

Exclusion Criteria:

• Hypersensitivity to study medication
• Genetic abnormality or disease of clotting system
• Prior major surgery or bleeding
• Other protocol-defined inclusion/exclusion criteria may apply